Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are one such class of antihyperglycemic that has demonstrated efficacy for people with diabetes across the spectrum of CV10 and kidney disease outcomes.11,12 Despite evidence that GLP-1RAs may be beneficial in managing chronic kidney disease (CKD) in people living with diabetes,12 they are largely unaccounted for in contemporary guidelines for kidney transplant recipients. Here, GLP1R is linked to diabetes mellitus.